Strongbridge Biopharma plc
Strongbridge Biopharma plc (SBBP): 3 pipeline candidates · ~20 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
20.1 months
0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Strongbridge Biopharma plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$63.8M
Quarterly Burn
$9.8M
Runway
20.1 mo
Revenue
$10.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| keveyis | Approved |
| recorlev | Phase 3 |
| veldoreotide | Preclinical |
Frequently asked questions
How many drug candidates are in Strongbridge Biopharma plc's pipeline?
Strongbridge Biopharma plc (SBBP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Strongbridge Biopharma plc's lead drug candidate?
Strongbridge Biopharma plc's most advanced tracked candidate is keveyis (Approved) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.
What is Strongbridge Biopharma plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Strongbridge Biopharma plc has approximately 20.1 months of cash runway.
Who is the CEO of Strongbridge Biopharma plc?
John H. Johnson is the chief executive officer of Strongbridge Biopharma plc (SBBP).
Get the full picture on Strongbridge Biopharma plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.